Hiroshi Kobe
Overview
Explore the profile of Hiroshi Kobe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kobe H, Okuda M, Yoshida T, Oga T, Ito K
Intern Med
. 2025 Feb;
PMID: 39993752
Objective Short-acting β agonists (SABAs) are key drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD). A high-flow nasal cannula (HFNC) is widely used for respiratory failure....
2.
Kobe H, Ito A, Nakanishi Y, Miyazaki Y, Takahashi H, Toyota Y, et al.
Cureus
. 2024 Jul;
16(6):e61542.
PMID: 38957255
Background The diagnosis of complex lung disease (MAC-LD) requires two or more positive sputum cultures. Few reports have examined the usefulness of adding liquid culture to conventional solid culture for...
3.
Kobe H, Hamao N, Niwa T, Ishida T
Cureus
. 2024 Jun;
16(5):e60530.
PMID: 38887334
Secondary pulmonary alveolar proteinosis (SPAP) is one of the diffuse parenchymal lung diseases, and the utility and safety of transbronchial lung cryobiopsy (TBLC) for diagnosing SPAP are unknown. A case...
4.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, et al.
Cancer Med
. 2023 Nov;
12(23):21097-21110.
PMID: 37948122
Background: Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non-small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing...
5.
Ito A, Ishida T, Nakanishi Y, Kobe H, Tokioka F
Respirology
. 2023 Apr;
28(7):677-680.
PMID: 37105899
No abstract available.
6.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, et al.
Thorac Cancer
. 2023 Mar;
14(11):1004-1011.
PMID: 36866788
Background: Patients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure. Methods: We...
7.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, et al.
Eur J Cancer
. 2022 Dec;
179:15-24.
PMID: 36470023
Introduction: Although osimertinib is a standard first-line treatment for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, the incidence rate of pneumonitis associated...
8.
Kobe H, Yokoe S, Ishida T
Thorac Cancer
. 2022 Nov;
14(2):210-213.
PMID: 36450693
Cryptococcosis is an invasive fungal infection that can occur in cancer patients. A case of pulmonary cryptococcosis in a patient treated with erlotinib + ramucirumab for epidermal growth factor receptor...
9.
Ando C, Ichihara E, Yokoyama T, Inoue K, Tamura T, Fujiwara K, et al.
J Cancer Res Clin Oncol
. 2022 Oct;
149(8):4933-4938.
PMID: 36308525
Background: Combination therapy with immune checkpoint inhibitors (ICIs) and chemotherapy (ICI + chemotherapy) has become the standard first line treatment for driver oncogene-negative advanced non-small-cell lung cancer (NSCLC). However, it...
10.
Kobe H, Momose M, Miyazaki Y, Nishihara C, Yoshida T, Ishida T
Chest
. 2022 Oct;
162(4):e165-e168.
PMID: 36210108
A 73-year-old man with fever and fatigue presented to his doctor. He had a history of smoking (52 pack-years) and COPD on home oxygen therapy. The patient had no significant...